GERD burden (GERD-en?)
|
|
- Gervase Chambers
- 6 years ago
- Views:
Transcription
1 GERD burden (GERD-en?) Controversies in the Upper GI Tract Jeffrey Fox, MD, MPH UCSF Primary Care Medicine: Update 2012 Very common 25% of Americans use antacids/antisecretory meds 3X/mo $8 billion/year spent antacids/h2rb/ppi Detrimental effects on quality of life found with symptoms as infrequent as once weekly Ronkainen et.al. Aliment Pharmacol Ther 2006 Defining GERD Symptom pattern heartburn, regurgitation, dysphagia How often is disease Pathologic lesion erosive esophagitis Combo of symptoms and esophagitis highly specific (97%) vs. ph testing What about those with the symptoms but without the lesion NERD Gold-standard ph monitoring best but imperfect Whom should I treat empirically? Typical symptoms No alarm features At least partial relief with OTC measures Age <55
2 Lifestyle measures Raise head of bed Don t eat late; >3 hours between meal and bedtime Avoid fatty foods, caffeine, alcohol, citrus, tomato, peppermint Stop smoking Weight loss Stop offending meds Lifestyle measures Systematic review of effectiveness of common measures in reducing symptoms Randomized controlled trials: NONE Retrospective/case-control studies: Elevating head of bed yes Sleeping in left lateral decubitus position yes Losing weight yes (Now USPSTF grade B rec) Dietary measures No (!!) Included tobacco/alcohol cessation Kaltenbach, et.al. Arch Intern Med, 2006 Offending meds Empiric therapy Decrease LES pressure Calcium channel blockers Nitrates Theophylline Anticholinergics (TCAs, antihistamines) HRT Mucosal injury Tetracyclines Quinidine ASA/NSAIDs Bisphosphonates Potassium Iron H2RAs (ie H2 blockers) Step-up approach Eliminate symptoms in 50% with BID dosing Maintains remission in only about 25% of patients Appropriate empiric therapy in setting where cost difference between H2RA and PPI is large
3 Empiric therapy PPIs Effective for symptom relief and esophagitis in 85-90% once-daily dosing PPI test 83% sensitive compared to ph probe/ esophagitis gold standard Fass, et.al. Aliment Pharacol Ther, 2000 In primary care GERD symptom population, likelihood ratio of positive PPI test 1.2 (CI ) for ph-proven GERD relative to negative PPI test Aanen, et.al. Aliment Pharacol Ther, 2006 PPIs: Which one? 6 agents (omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and dexlansoprazole) all FDA approved and effective for GERD Esomeprazole (Nexium) decreases number hrs ph held above 4 at standard doses and heals esophagitis in slightly higher % of patients than others Miner,et al. Am J Gastroenterol, 2003
4 PPIs: Which one? However, NO AGENT SUPERIOR for symptom relief when agents compared head to head. HENCE: Choose the one on formulary; otherwise, would choose omeprazole because generic PPIs: How long? Erosive esophagitis 8 weeks Barrett s esophagus lifetime GERD symptoms 4-8 weeks, then on demand Many need long term maintenance therapy GERD relapses after cessation of therapy Sandmark, et.al. Scand J Gastroenterol, 1988 Long-term PPI Safety Endocrine Serum gastrin elevated theoretical trophic risk in gestation 1 st trimester pregnancy use: no increase in birth defects Pasternak B, et al. NEJM, 2010 Gastric carcinoids in rats, none in humans (except one with MEN) Nutritional Can lower cobalamine (B12) absorption Not thought to significantly affect iron homeostasis Dent, et.al. Gut, 1994 Klinkenburg-Knol, et.al. Ann Int Med, 1994
5 Long-term PPI Safety Hip fracture Case/control study in UK Duration Hip fracture of therapy Adjusted OR (CI) 1yr 1.22 ( ) 2yr 1.41 ( ) 3yr 1.54 ( ) 4yr 1.59 ( ) Yang et.al. JAMA 2006 Long-term PPI Safety Hip fracture Higher risk for high dose (over 1.75 doses per day) OR 2.65 for high dose/long term Lower risk for H2RB though still statistically significant increased risk. Cases also were more likely than controls to take: anxiolytics (OR 1.76), antidepressants (2.17), NSAIDs (1.38), antipsychotics (3.34), antiseizure meds (3.42), antiparkinsonian meds (3.83), corticosteroids (2.25), and thyroxine (1.40) FDA warning Yang et.al. JAMA 2006 Long-term PPI Safety Why hip fractures? Theoretically, acid inhibition interferes with calcium absorption in the small intestine However, PPIs do NOT appear to be associated with osteoporosis or accelerated bone mineral density loss Targownik LF, et al. Gastroenterol, 2010 Confounders? Osteoclast proton-pump inhibition? PPI vs aspirin Number needed to harm (NNH) = number of people who need to be prescribed medication to have 1 complication above the level of placebo GI hemorrhage on annual basis with aspirin treatment: NNH 100 Hip fracture on annual basis with PPI treatment: NNH 330
6 Long-term PPI Safety Community-acquired infections Clostridium difficile: Case/control study in UK 1 For people taking PPIs: OR 2.9 For people taking H2RBs: OR 2.0 Community acquired pneumonia: meta-analysis of case-control studies 2 OR for CAP 1.36 for PPI relative to controls Significant heterogeneity and only modest risk Theoretical basis is decrease in gastric acidity may be permissive to enteric infection (in Cdiff) and reflux/microaspiration (CAP) Dial et.al. JAMA Johnstone J, et.al. Aliment Pharmacol Ther Long-term PPI safety Hypomagnesemia FDA safety alert March 2011: Hypomagnesemia is rare but possible adverse effect from long-term PPI use Special care in patients also on other meds that can cause hypomg (eg diuretics, digoxin) Can result in muscle spasm, seizures, and cardiac events What about PPIs and Plavix? Plavix effect on platelets thought to be mitigated by PPIs in ex-vivo platelet aggregation studies (P450 CYP2C19) Observational data mixed on event rates Ho PM et al, JAMA 2009 Ray WA et al. Ann Intern Med 2010 Banergee S et al. Am J Cardiol 2011 Randomized trial of PPI + plavix vs. plavix alone (COGENT) no difference in cardiac events PPI/plavix group had 50% bleeding risk Bhatt, et al. NEJM 2010 ACC/AHA/ACG position In patients taking clopidogrel+asa 2008 ACC/AHA/ACG take PPI co-therapy 2009 FDA BOXED WARNING on omeprazole/esomeprazole plus clopidogrel 2010 ACC/AHA/ACG position update: There may be an important interaction In high risk patients for UGI bleed, benefits of PPI co-therapy outweigh risks In average risk patients, case-by-case approach Use non-omeprazole/esomeprazole PPIs when on plavix if PPI is needed/advised
7 Long-term PPI Safety PPIs are made of rubber No prospective randomized data proving harm Enough retrospective evidence of potential harm to be cautious Needs further study Questions raised in a given patient: Does my patient need this medication? Can I get him/her off of it or onto a less potent one? PPI maintenance: On-demand Symptom-driven therapy Single-dose (true on-demand ) Short course ( intermittent therapy ) Controlled by patients, not providers PPI on-demand therapy may be most cost-effective of all maintenance strategies Fewer meds Fewer adverse reactions (realized & potential) Fewer office visits Gerson, et.al. Am J Gastroenterol, 2000 Refractory patients Standard dosing regimen once-daily not working for classic symptoms after 1 month trial once-daily PPI OPTIONS: Twice-daily (breakfast/dinner) eg omeprazole 20 BID Add H2RA for nocturnal acid breakthrough Recently shown to be of little benefit, but anecdotally some improve Vakil et.al. Aliment Pharmacol Ther, 2006 Twice-daily double dose (eg omeprazole 40 BID) Can be helpful in subset Leite, et.al. Am J Gastroenterol, 1996 Other agents: sucralfate, prokinetics, (treat concomitant gastric emptying disorder), baclofen GERD and stress Animal model Rats subjected to stress have more esophageal mucosal permeability and dilated intercellular spaces relative to controls Farre R et.a. Gut 2007 Acid exposure in humans is similar in stress and non-stress, but perception of acid higher in stress
8 Non-erosive GERD: NERD! Endoscopy-negative GERD, functional heartburn, IBS of the esophagus 50-70% of those with classic GERD symptoms Less likely to have abnormal ph study Mechanisms Hypersensitivity Disordered motility Psychological factors High correlation with female gender, functional GI disorders, mood disorders Can respond to mix of acid reducing meds, TCAs, anxiolytics, psychotherapy If GERD-like symptoms but no better on acid reduction: STOP/REDUCE ACID REDUCTION THERAPY TRY SOMETHING ELSE Chey WD, Am J Med, 2004 Meds don t work: What else? Referral to specialist Anti-reflux surgery Endoscopic intervention Naturopathic/alternative GERD alarm symptoms Dysphagia Odynophagia Weight loss Bleeding (melena, hematemesis) Anemia Anorexia Nausea/vomiting Severe or persistent symptoms despite Rx
9 The further evaluation Endoscopy Ambulatory ph testing/impedence testing Esophageal manometry Barium esophagram Other Laryngoscopy Cardiac stress testing PFTs Serum gastrin Anti-reflux surgery Defect in mechanical barrier to reflux corrected Laparoscopic Nissen fundoplication Success largely operator dependent Best candidates: those with GERD on both subjective and objective measures Poor candidates: poor surgical candidates, atypical symptoms Initial success 90-95% in eliminating sx and healing esophagus (many studies) Medical vs. Surgical Rx GERD and asthma year follow-up No significant difference between medical and surgical arms in physical and mental well-being or overall satisfaction 62% of surgical patients taking meds for GERD symptoms?increased mortality in surgical arm % 62% Percent using GERD meds Medical Surgical Acid reflux can cause bronchoconstriction NIH asthma guidelines recommend investigating GERD in asthma patients, even without GERD symptoms Randomized trial Nexium vs placebo in asthmatics with no or minimal GERD sx No difference between groups in symptoms or PFTs, even those with silent reflux Spechler, et.al. JAMA 2001 American Lung Association Asthma Clinical Research Centers, NEJM, 2009
10 GERD and extraesophageal sx Laryngitis, chronic cough, asthma USPSTF position: Treatment recommended when extraesophageal symptoms accompany typical esophageal symptoms (grade B) Treatment not recommended in absence of typical esophageal symptoms (grade D) Kahrilas PJ, et al. Gastroenterol 2008 Remember GERD is chronic disease meds control most people s symptoms to a manageable level (75-80% improvement) but do not eliminate them Reassurance is enormous part of job Empiric therapy appropriate for uncomplicated disease; alarm symptoms should warrant GI referral PPIs are OK but stop if not helping COX-2 inhibitors and GI safety Medications and UGI bleeding Main advantage of COXIBs has been fewer peptic ulcers and better tolerability than nonselective NSAIDs Supported by recent Cochrane Meta-Analysis Compared to standard NSAIDs, COXIBs had: Fewer gastroduodenal ulcers (RR 0.26; CI ) Fewer ulcer complications (RR 0.39; CI ) Fewer withdrawals for GI sx (RR 0.65;CI ) Need to weigh higher cardiovascular risk, which appears to be directly correlated to degree of Cox- 2 selectivity Rostom A, et.al. Clin Gastroenterol Hepatol 2007
11 NSAID gastroprotection In patients taking NSAIDs, which is safer? COX-2 inhibitor vs. standard NSAID plus PPI Medicare peptic ulcer hospitalizations/yr Nonselective NSAID/no gastroprotection: 5.6/1000 Nonselective NSAID plus PPI: reduced 54% (CI 27-72%) Cox-2 inhibitor plus PPI: reduced 50% (CI 27-66%) No significant difference between to groups Ray WA, et.al. Gastroenterol 2007 SSRIs and UGI bleeding Current, recent, or past SSRI use is associated with a 1.67, 1.88, and 1.22 OR of an UGI bleed Risk was increased with concurrent use of NSAIDs or aspirin and decreased with concurrent use of PPI TCAs did not show this association Inhibition of platetet activity possible mechanism Dall M, et al. Clin Gastroenterol Hepatol 2009 Low dose aspirin and GIB Meta-analysis of dosages mg/day RR* Decreased overall mortality 0.93 Increased risk of GI bleeding 1.55 In combination with aspirin, vs aspirin alone Other antiplatelet/anticoagulants 1.86 PPI 0.34 *All statistically significant Stopping aspirin after GI bleed? Patients with peptic ulcer bleed on aspirin randomized to PPI + aspirin vs. PPI + placebo Rebleed risk after 8 weeks All-cause mortality after 8 weeks PPI plus baby aspirin PPI plus placebo 10% 5% 1% 13% Lanas A et al. Clin Gastroenterol Hepatol 2011 Sung, JJY, et.al, Ann Int Med, 2010
12 Approach to dyspepsia Dyspepsia Pain or discomfort in epigastrium Numerous possible approaches H.pylori test and treat Empiric antisecretory (H2RB or PPI) Endoscopy H.pylori: Who has it? Prevalence in adults in mid 1990s 50% developed world 80% developing world Risk factors Lower socioeconomic status Poor living conditions, eg crowding, lack of running water, housing density H.pylori and ethnicity NHANES stored sera from Non-Hispanic White Mexican American African American Prevalence 26.2% 61.6% 52.7% Odds ratio compared to White NA 6.3 ( ) 3.9 ( ) Pounder RE, et.al. Aliment Pharmacol Ther 1995 Everhart JE et.al. J Infect Dis 2000
13 H.pylori: Declining prevalence Within a given country, appears to relate to improvements in economic status and sanitation In Japan, H.pylori seropositivity Born prior to 1950: > 70% Born : 45% Born after 1960: 25% H.pylori associations Duodenal and gastric ulcers Gastric cancer MALT Gastric adenoca Atrophic gastritis/gastric intestinal metaplasia Functional dyspepsia Asaka M, et.al. Gastroenterology 1992 H.pylori and ulcers Strong association between H.pylori and duodenal ulcers, less strong for gastric Synergistic effect with H.pylori and NSAIDs in ulcer incidence Effective eradication of H.pylori clearly reduces ulcer recurrence H.pylori and gastric cancer H.pylori is associated with gastric adenocarcinoma and its precursors Treatment of H.pylori in MALT lymphoma when early stage can be curative Treatment of H.pylori may reduce risk of gastric adenocarcinoma Wong BC, et.al. JAMA 2004
14 H.pylori and functional dyspepsia Controversial association between functional dyspepsia (FD) and H.pylori Evidence that H.pylori eradication in FD improves symptoms is mixed Meta-analysis shows SMALL but statistically significant improvement in HP eradication in FD 1 NNT 18 for 1 improvement over placebo 1 Moayyedi P, et.al. Cochrane Database Syst Rev 2005 H.pylori testing Serology Urea breath test Stool antigen Endoscopic biopsy Histology Culture H.pylori treatment First-line therapy (AOC) X days 1 Amoxacillin 1000mg BID Eradication Clatrithomycin 500mg BID 80% PPI standard dose BID PCN allergic: Switch Flagyl 500mg BID for Amoxacillin 7 days nearly as effective as days 2 Treatment-failures, numerous regimens 1 Chey WD, et.al. Am J Gastroenterol Fuccio L, et.al. Ann Intern Med 2007 H.pylori sequential vs standard Eradication (intention to treat) Eradication Sequential PPI + Amox X 5 days then PPI + Biaxin + Flagyl X 5 days Standard PPI + Amox + Biaxin X 14 days 85.9% 75% p = (per protocol) 92.6% 85% p=0.019 Resistance to standard triple therapy increasing Sequential therapy may improve eradication over standard triple therapy Kim YS, et al. Aliment Pharmacol Ther 2011
15 H. Pylori and GERD Try to distinguish GERD symptoms from dyspepsia!! Often difficult overlapping and multiple complaints Poor correlation between patient & clinician symptom assessement (kappa ) Treatment of H.pylori may WORSEN GERD H.pylori infection in some observational studies lower in patients with GERD symptoms Randomized trial did NOT confirm GERD higher in H.pylori treated patients Use of endoscopy in dyspepsia Always with alarm symptoms Alarm symptoms poor predictor of organic pathology Failure to improve despite numerous rounds of empiric therapy Appropriate age cut off is controversial Guidelines vary from UGI cancer rare prior to age 55 McColl, et.al. Am J Gastroenterol 2005 Moayyedi, et.al. Gastroenterol 2001 yes Alarm symptoms or age > 55? no normal How to approach a patient with dyspepsia abnormal yes no no yes findings Symptom resolution? neg no yes
16 Functional dyspepsia Pain in epigastrium without identifiable organic cause (endoscopy negative) What s wrong then? Not clear. Motility disorder? Visceral hypersensitivity? Psychosocial factors? Altered brain-gut axis? Overlap with other functional GI disorders (eg NERD, IBS) 1 2/3 of pts presenting with dyspepsia have FD Functional dyspepsia: Medical Management Therapy NNT PPI 9 H.pylori eradication 18 Prokinetics 4 (included cisapride) TCA/anxiolytics 4 Anatacids, bismuth, sucralfate No better than placebo NNT = Number needed to treat = 1/effect size 1 Corsetti M et.al. Am J Gastroenterol 2004 Saad RJ, et.al. Aliment Pharmacol Ther 2006 Functional dyspepsia: Anything else? Psychotherapy Individual trials suggest benefit Systematic review unable to synthesize 1 Studies too diverse High dropout rates in control groups Complementary alternative medicine 2 STW 5 (Iberogast) Capsaicin red chili pepper Artichoke leaf extract Soo S et.al. Am J Gastroenterol Saad RJ et.al. Aliment Pharmacol Ther
Art Burne. Art Burne. Updates in the upper GI tract
Updates in the upper GI tract Jeffrey Fox, MD, MPH UCSF Primary Care Medicine: Update 2010 Art Burne 45 yo white overweight male Has substernal burning once per week before he goes to sleep at night No
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease
ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease Philip O. Katz MD 1, Lauren B. Gerson MD, MSc 2 and Marcelo F. Vela MD, MSCR 3 1 Division of Gastroenterology, Einstein
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationRefractory GERD. Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida
Refractory GERD Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida Objectives Define the terminology associated with refractory
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationBurning Issues in Gastroesophageal Reflux Disease (GERD)
3:45 4:45pm Burning Issues in GERD SPEAKER Prateek Sharma, MD, FACG, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Prateek Sharma, MD, FACG, FACP,
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationThe PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures
The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off
More informationSafety Of. long-term PPI. Layli Eslami, MD Tehran, 1393
Safety Of long-term PPI Layli Eslami, MD Tehran, 1393 n The introduction of PPIs in the late 1980s optimized the medical treatment of acidrelated disorders n In some cases such as GERD patients given the
More informationLONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS. Jihane Naous, M.D.
LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS Jihane Naous, M.D. Objectives Identify the conditions supported by AGA/ACG guidelines necessitating long-term use of daily PPIs, Recognize which
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationFunctional Dyspepsia
Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology
More informationDisclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None
Heartburn and Barrett s Esophagus None Disclosures Christian Mathy, MD University of California, San Francisco 2015 Heartburn and Barrett s Esophagus Heartburn and GERD GERD therapy Extraesophageal GERD
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationPractical Guide to Safety of PPIs What to Tell Your Patient. Proton Pump Inhibitors
Practical Guide to Safety of PPIs What to Tell Your Patient Joel E Richter, MD, FACP, MACG Professor and Director Division of Digestive Diseases and Nutrition Joy Culverhouse Center for Esophageal Diseases
More informationGERD: A linical Clinical Clinical Update Objectives
GERD: A Clinical Update Jeff Gilbert, M.D. University i of Kentucky Gastroenterology 11/6/08 Objectives To review the basic pathophysiology underlying gastroesophageal reflux disease To highlight current
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationFunctional Heartburn and Dyspepsia
Functional Heartburn and Dyspepsia Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina Objectives Understand the means of diagnosing functional heartburn
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More informationSpeaker disclosure. Objectives. GERD: Who and When to Treat 7/21/2015
GERD: Who and When to Treat Eugenio J Hernandez, MD Gastrohealth, PL Assistant Professor of Clinical Medicine, FIU Herbert Wertheim School of Medicine Speaker disclosure I do not have any relevant commercial
More information6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other
Peptic Ulcer Disease and Dyspepsia John M. Inadomi, MD Professor of Medicine UCSF Chief, Clinical Gastroenterology San Francisco General Hospital Case History 49 y/o woman complains of several months of
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationQUICK QUERIES. Topical Questions, Sound Answers
QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationReflux of gastric contents, particularly acid, into the esophagus
Heartburn Reflux of gastric contents, particularly acid, into the esophagus Patient assessment with GERD 1-signs and symptoms The hallmark of typical symptom of GERD is heartburn (restrosternal),acid regurgitation,
More informationA C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R
PPI DEPRESCRIBING Canadian Deprescribing Network (CaDeN) goals are to: Reduce harm by raising awareness and cutting risky prescriptions for seniors by 50% by 2020. Promote health by ensuring access to
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationSASKATCHEWAN REGISTERED NURSES ASSOCIATION
DEFINITION Reflux of gastric contents into the esophagus, which results in esophageal irritation or inflammation. IMMEDIATE CONSULTATION REQUIRED IN THE FOLLOWING SITUATIONS Dysphagia (solid food, progressive)
More informationNumber of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI
Clinical Approach to the Patient t with Dyspepsia William D. Chey, MD, FACG Professor of Medicine University of Michigan Prevalence of Endoscopic Findings in Individuals with Dyspepsia Systematic Review
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationTBURN TBURN BURN ARTBURN EARTBURN EART HEARTBURN: HOW TO GET IT OFF YOUR CHEST
TBURN BURN TBURN ARTBURN. EARTBURN EART N EARTBURN HEARTBURN: HOW TO GET IT OFF YOUR CHEST Do you sometimes wake up at night with a sharp, burning sensation in your chest? Does this sometimes happen during
More informationGastro esophageal reflux disease DR. AMMAR I. ABDUL-LATIF
Gastro esophageal reflux disease )GERD( DR. AMMAR I. ABDUL-LATIF GERD DEFINITION EPIDEMIOLOGY CAUSES PATHOGENESIS SIGNS &SYMPTOMS COMPLICATIONS DIAGNOSIS TREATMENT Definition Montreal consensus defined
More informationRefractory GERD : case presentation and discussion
Refractory GERD : case presentation and discussion Ping-Huei Tseng National Taiwan University Hospital May 19, 2018 How effective is PPI based on EGD? With GERD symptom 75% erosive 25% NERD Endoscopy 81%
More informationGastroesophageal Reflux Disease, Paraesophageal Hernias &
530.81 553.3 & 530.00 43289, 43659 1043432842, MD Assistant Clinical Professor of Surgery, UH JABSOM Associate General Surgery Program Director Director of Minimally Invasive & Bariatric Surgery Programs
More informationPerplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver
Perplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationHold the Wrap! There is so much more to be done!
Hold the Wrap! There is so much more to be done! (Well, a few things that can be done.) (Well, not all that much, really ) (But Blair has never killed anyone with a PPI!) Nicholas Shaheen, MD, MPH Center
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationNon-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics
Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic
More informationRisk of GI Bleeding and Use of PPIs
Risk of GI Bleeding and Use of PPIs ESC 211 August 28, 211 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Associate Professor of Medicine, Harvard
More informationManagement of Functional Dyspepsia (FD)
Management of Functional Dyspepsia (FD) Amy S. Oxentenko, MD, FACG Program Director and Associate Chair, IM Associate Professor of Medicine Mayo Clinic, Rochester Outline Define functional dyspepsia (FD)
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationEffective Health Care
Effective Health Care Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease Executive Summary Background Gastroesophageal reflux disease (GERD), defined as weekly heartburn
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationKK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011
KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology
More informationOutline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments
Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology
More informationGERD: Pitfalls and Pearls
GERD: Pitfalls and Pearls Gary W. Falk, M.D., M.S. Professor of Medicine Division of Gastroenterology Perelman School of Medicine of the University of Pennsylvania Conflicts of Interest Nothing to disclose
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationGASTROESOPHAGEAL REFLUX
DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (404) 270-7479 GASTROESOPHAGEAL REFLUX DEFINITION: *MONTREAL CONSENSUS DEFINED GERD AS A CONDITION WHICH
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationHeartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus.
WHILE almost everyone experiences mild heartburn from time to time and many individuals have some antacids or another medication on hand for its relief, talk to your doctor, if you have heartburn more
More informationFast Facts In OTC PPI s
Page 1 Fast Facts in OTC PPI s Fast Facts in OTC PPIs James M. Scheiman, MD Professor of Internal Medicine Division of Gastroenterology University of Michigan Medical School Ann Arbor, Michigan This program
More informationFast Facts In OTC PPI s
Page 1 Fast Facts in OTC PPI s Fast Facts in OTC PPIs James M. Scheiman, MD Professor of Internal Medicine Division of Gastroenterology University of Michigan Medical School Ann Arbor, Michigan This program
More informationUpdates in Evaluation and Management of Dyspepsia and H. Pylori Infection
Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Isabel Lee, MD Associate Professor of Health Sciences UCSF Department of Family and Community Medicine Disclosures None 2 Session
More informationPutting Chronic Heartburn On Ice
Putting Chronic Heartburn On Ice Over the years, gastroesophageal reflux disease has proven to be one of the most common complaints facing family physicians. With quicker diagnosis, this pesky ailment
More informationMY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT?
MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT? Clarence Wong MD FRCPC Associate Professor FACULTY/PRESENTER DISCLOSURE Faculty: Clarence Wong Relationships with commercial interests: Grants/Research
More informationIs Rabeprazole A Safe Treatment for Gastroesophageal Reflux Disease in Children Ages 1-16 years?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Rabeprazole A Safe Treatment for Gastroesophageal
More informationManagement of dyspepsia in adults in primary care
Dyspepsia Management of dyspepsia in adults in primary care June 2005. The recommendations on referral for endoscopy in this NICE guideline have been amended in line with the recommendation in the NICE
More informationRefractory GERD: What s a Gastroenterologist To Do?
Refractory GERD: What s a Gastroenterologist To Do? Philip O. Katz, MD, FACG Chairman, Division of Gastroenterology Einstein Medical Center Clinical Professor of Medicine Jefferson Medical College Philadelphia,
More informationGERD, peptic ulcer disease, and celiac disease: updates from the upper GI tract
GERD, peptic ulcer disease, and celiac disease: updates from the upper GI tract Primary Care Internal Medicine, October 15, 2018 Kyle Staller, MD, MPH Director, Gastrointestinal Motility Laboratory Center
More informationGastroesophageal Reflux Disease (GERD)
Quality Department Guidelines for Clinical Care Ambulatory GERD Guideline Team Team Leader Joel J Heidelbaugh, MD Family Medicine Team Members R Van Harrison, PhD Learning Health Sciences Mark A McQuillan,
More informationYou May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Pantoprazole (Pantoloc, Panto IV )
You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Esomeprazole (Nexium ) Omeprazole (Losec, Olex ) Pantoprazole (Pantoloc, Panto IV ) Pantoprazole
More informationOptimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI
Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University
More informationDisclosures. Gastroesophageal Reflux Disease. Gastroesophageal Reflux Disease
Kunal Jajoo, MD Brigham and Women s Hospital July 2012 Disclosures Spouse is a physician employed by Boston Scientific Corporation The content of this lecture equitably discusses products of multiple companies
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 5 March 2007 Current Practice Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions
More informationClass Update: Proton Pump Inhibitors and Histamine 2 Receptor Antagonists
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationProton Pump Inhibitors:
Proton Pump Inhibitors: How bad could they be? Andrea Flanagan, Pharm.D. Iowa City VA Medical Center PGY-1 Pharmacy Resident Objectives for Pharmacists At the end of this presentation PHARMACISTS should
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationGERD. Gastroesophageal reflux disease, or GERD, occurs when acid from the. stomach backs up into the esophagus. Normally, food travels from the
GERD What is GERD? Gastroesophageal reflux disease, or GERD, occurs when acid from the stomach backs up into the esophagus. Normally, food travels from the mouth, down through the esophagus and into the
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Achalasia, barium esophagography for, 57 58 Acid pocket, 18 19 Acid-sensing ion, 20 Acupuncture, 128 Adiponectin, in obesity, 166 ADX10059 metabotropic
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More information2018 CONSENSUS UPDATES + RISKS/BENEFITS OF PPI USE
2018 CONSENSUS UPDATES + RISKS/BENEFITS OF PPI USE IN INFANT GERD SWEDISH MEDICAL CENTER JONAH ESSERS, MD, MPH OBJECTIVES Highlight the 2018 updates to infant GERD recommendations Provide an update on
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationEpidemiology of Peptic Ulcer Disease
Epidemiology of Peptic Ulcer Disease Introduction Peptic Ulcer Disease (PUD) is disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active
More informationAmerican College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology
More informationGastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) Acid Reflux Acid reflux occurs when acid from the stomach moves backwards into the esophagus. Heartburn Heartburn is a symptom of acid reflux and GERD. It may feel
More informationProfessor Richard Gearry
Professor Richard Gearry Consultant Gastroenterologist Christchurch Hospital, Professor of Medicine, University of Otago, Christchurch 8:30-9:25 WS #140: A Revolution in Reflux: Tackling the Therapeutic
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More information